Hypertension is known as a cause of endothelial cell damage and it activates humoral immunity. Therefore, it may modulate the anti-beta2-glycoprotein I antibody (aPGPI) to commit for thrombosis. To elucidate the relation between afGPI and hypertension in cerebral ischemia, the blood a3GPI level was examined in healthy subjects, hypertensive subjects, and patients with cerebral ischemia with and without hypertension, respectively. The results Address correspondence and reprint requests to However, the blood apGPI level showed no difference between healthy individuals and hypertensive subjects, nor cerebral ischemia patients with and without hypertension. The serum globulin level did not change among them. Therefore, apGPI displays a vital role for cerebral ischemia in both hypertensive and normotensive subjects. An activation of humoral immunity involving a3GPI warrants further investigation in cerebral ischemia.
showed that the blood apGPI level increased in cerebral ischemia patients with hypertension rather than hypertensive subjects, and patients without hypertension rather than healthy individuals.
Although anti-beta2-glycoprotein I antibody (af3GPI) has been identified to increase the risk of cerebral ischemia in patients with antiphospholipid antibody syndrome (APS) or systemic lupus erythrematosus (SLE) , it is recently shown to carry a high risk in non-APS/SLE patients also.
The frequency of increased apGPI in cerebral ischemia is estimated to be 14% in them (1) . The apGPI initially draws much attention because an increase of antiphospholipid antibody is found in cerebral ischemia among young adults (2) or individuals without cardiovascular risk factors (3, 4) . This finding allies to an activation of humoral immunity in the development of cerebral ischemia in these populations, but is beyond the traditional concept of cerebral ischemia that is prevalent for elderly patients and associated a high frequency of cardiovascular risk factors.
Although controversial results have been subsequently reported (5, 6) , the prosperity of inflammatory theory has gathered mounting evidence of humoral immunity displaying a critical role for thrombosis and atherogenesis (7) .
Hypertension is still the leading cause for cerebral ischemia worldwide regardless of ethnicity, gender, and age. In contrast to previous concepts, hypertension is currently known to participate actively in the physiology of endothelial cells, thrombocytes, and clotting factors to maintain the Virchow triad. Hypertension is also involved in humoral immunity (8) and may modulate a,GPI to commit for thrombosis. Unfortunately, the relation between a3GPI and hypertension and other cardiovascular risk factors is barely mentioned. Therefore, this study is designed to elucidate the relation between a,BGPI and hypertension and their roles in cerebral ischemia.
MATERIALS AND METHODS
The roles of autoimmunity and cerebral ischemia are being conducted in my laboratory. In this study, the aim is to find out: a) the relation between apGPI and hypertension; b) the role of apGPI in hypertensive patients with and without cerebral ischemia; and c) the role of af3GPI for cerebral ischemia in normotensive and hypertensive patients.
Study Population
Four groups of subjects were enrolled in this study. Group I subjects were healthy individuals who had unremarkable medical histories. They were healthy volunteers, who were hospital employees or individuals, under neurologic examination. Group II subjects were hypertensive patients without symptomatic cerebral ischemia or focal neurologic deficit. Group III subjects were cerebral ischemia patients without hypertension. Group IV subjects were cerebral ischemia patients with hypertension.
Patients with noncardiac cerebral ischemia were enrolled in this study (1, 9, 10) . An exclusion of cardiac disease was based on a negative finding in cardiac echogram and electrocardiogram. In this study, further exclusions included: a) a previous or current history of SLE, APS or collagen disease; b) a recent craniofacial trauma within 3 months; c) a consumption of herb remedy, anticoagulant, estrogen, androgen, or corticosteroid; d) an abnormal renal (serum creatinine > 1.4 mg/dL) or hepatic (SGOT > 40 IU/L or cirrhosis) function; e) an abnormal thyroid or adrenal function; f) a positive antinuclear factor ( > 1:160); g) diabetes mellitus; or h) transient ischemic attack.
The diagnosis of APS was according to the International Consensus Statement on Preliminary Criteria for the Classification of the Antiphospholipid Syndrome (11) . The diagnosis of SLE was according to the American College of Rheumatology with an updated revision (12, 13) . Hypertension was defined as an increase of systole over 160 mmHg and/or diastole over 90 mmHg in three separate measurements after 15 minutes rest in supine laying.
Baseline Examination
Each individual received detailed neurologic examination, physical examination and risk factor survey, including glucose, total proteins, albumin, globulins, uric acid, total cholesterol, triglyceride, aspartate and alanine aminotransferase, creatinine, complete blood cell count, erythrocyte sedimentation rate (Wintrobe method), fibrinogen, lupus anticoagulant, anticardiolipin antibody, a3GPI, and antinuclear antibodies.
Cranial computed tomography, head magnetic resonance imaging and angiography, carotid duplex and transcranial doppler were completed for all cerebral ischemia patients.
Venous blood was collected from antecubital vein by using a sterile vacutainer system after overnight fasting for 10 hours. Blood was mixed with 3.8% trisodium citrate (1:9 citrate: blood). For a,GPI, anticardiolipin antibody and lupus anticoagulant, blood was centrifuged within 1 hour after collection (Universal 16R Hettich Zentrifgen for 10 minutes at 3000 g under 4°C) to yield platelet-poor plasma. The platelet-poor plasma was aliquoted and stored at -20°C for batch measurement within 14 days. For complete blood cell count, blood was examined within 4 hours with Sysmex SE-9000 automated counter (Australian Diagnostics Corp, Sydney, Australia). Then glucose, total proteins, albumin, globulins, uric acid, total cholesterol, triglyceride, aspartate and alanine aminotransferase, and creatinine were examined within 2 hours after collection (Hitachi 7450 autoanalyzer, Tokyo, Japan).
Antiphospholipid Antibody Assays
ELISA method was used to measure the a,3GPI-IgG, anticardiolipin IgG antibody, and IgM antibody (Varelisa test-kit, Pharmacia & Upjohn, Germany). The lupus anticoagulant was determined by the dilute Russell's viper venom test (LA Screen/LA Confirm, Gradipore, Australia). The aIGPI IgG isotype was expressed as units per milliliter. In a,BGPI, the coefficient variance of intravariation was 4.2 and intervariation was 6.5. The cut-off level of anticardiolipin IgG-antibody isotype was 10 GPL/mL and IgM isotype was 6.0 MPL/mL. An abnormal lupus anticoagulant was defined as a prolongation of dilute Russell's viper venom test more than 1.2 fold after the mixing test (1, 9) .
Statistical Analysis
Descriptive statistics for continuous variables were reported by mean and standard deviation. Variance and one-way ANOVA were examined for continuous variables. For categorical variables, number and percentage of patients were given.
Categorical variables were evaluated with chi-square test or Fisher's exact test. A probability less than 0.05 was accepted to have significant difference.
RESULTS
There were 35 subjects in group I, 35 subjects in group II, 60 patients in group III, and 96 pa-tients in group IV, respectively. The age and gender did not differ among them. The arterial blood pressure was within reference range in groups I and III, but it increased in groups II and IV patients ( Table 1 ). The serum total proteins, albumin, globulins, uric acid, total cholesterol, triglyceride, aspartate and alanine aminotransferase, creatinine, and platelet count did not differ among these 4 groups of subjects (one-way ANOVA, p>0.05 in all variables).
The mean and one standard deviation value of blood apGPI level was 2.766 1 The variance blood af3GPI level showed no difference between group I and II subjects (1.258 vs 1.442, F=0.003, p=0.996), or between group III and IV patients (31.739 vs 51.450, F=0.003, p=0.955). However, a significant difference was found between group I subjects and III patients (F=7.337, p=0.008) while a marginal difference is found between group II and IV patients (F=3.887, p=0.048) (Fig. 1) . The chi-square test or Fisher's exact test was used to test these results. When the blood a3GPI level was set the cut-off point at 6.1 U/mL (mean plus three stan-dard deviations), no subject showed abnormally increased blood apGPI level in group I and II, but 11 patients in group III and 11 patients in group IV, respectively. A significant difference was still found between group I and III patients (Fisher's exact test, p=0.009), and a marginal difference was also achieved between group II and IV patients (Fisher's exact test, p=0.048). The blood a,BGPI level again showed no difference between group III and IV patients (X2=l.51, p>0.05).
Thus, these results support a) no change of blood a[GPI level in hypertensive from normotensive subjects; and b) an increase of blood aIGPI level in both normotensive and hypertensive cerebral ischemia patients.
DISCUSSION
In this series, an increase of blood afGPI level is demonstrated in cerebral ischemia patients with or without hypertension in comparing with hypertensive or healthy subjects, respectively. A vital role of afGPI for cerebral ischemia in both hypertensive and normotensive subjects is suggested. The blood apGPI level does not increase in my hypertensive patients. The role of a3GPI in hypertension is clearly mentioned in the following literature, including that Frostegard and associates (14) reported an increase of blood arGPI level in their 73 patients with borderline hyper- tension., Fiallo and colleagues (15) revealed a marginal association between af3GPI and hypertension in their 121 cerebral ischemia patients, and an increase of urine ap3GPI level was found in pre-eclamptic women (16) . However., Sherer and associates (17) did not find a difference of blood afoGPI level between their coronary artery syndrome patients with and without hypertension. These studies encompass patients with different diseases and definitions of hypertension, in which appeal with controversy among them. Regarding hypertension without cardiovascular complication, a different result is achieved between Frostegard and associates (14) and my study. It is not surprising to find a confliction because there are several differences between the two studies. First, all patients are men in their series. Second., the definition of hypertension is different between the two studies, for instance., it is 85 to 94 mmHg in diastole in their patients, but it is over 140 mmHg in systole or 90 mmHg in diastole in my series. Third, an ethnic difference of human leukocyte antigen genotypes for apGPI expression has been reported (18) but the depth of influence is unknown in my patients.
Simultaneously, Sherer and associates (1 7) did not find a difference in blood apGPI level between coronary artery syndrome patients with and without hypertension, although Fallio and associates (15) showed a marginal association between blood afpGPI level and hypertension in their cerebral ischemia patients. My result is similar to that of Fallio and associates (15) . These inconsistent results for aI3GPI in patients with cardiovascular complications may share some reasons in hypertensive patients without complication. A bias of data deriving from five single clinical reports cannot be eliminated. However, this controversy does not discard a different expression of humoral immunity in different stages or conditions. A number of serum proteins, such as E-selectin (19) , von Willibrand factor (20) , vascular endothelial growth factor and its soluble receptor (20) , or parathyroid hormone (21) , correlates directly or inversely to the magnitude of blood pressure in hypertensive subjects. The blood afpGPI level is modulated by the insulin resistance, insulin growth factor I-binding protein or blood insulin level (14) , which is related to the 7, severity and chronicity of hypertension. In both human and animals, humoral immunity changes along with the evolution of hypertension: the B cells become hyperactive and oversecrete immunoglobulins (22) (23) (24) (25) , and a diverse spectrum of autoantibodies also develops in gradual (26) . Regarding a,BGPI, it increases against the beta2glycoprotein I (PGPI)/phospholipids complex, formed by a binding of phospholipids that translocates from inner to outer cell membrane upon apoptosis and ,GPI in circulation. Epitopes in f3GPI/phospholipids complex provoke humoral reaction to produce a,GPI. Indeed, endothelial cell damage is identified in the early course of hypertension (27) . Therefore, an increase of blood afGPI level is found in Frostegard and colleagues' patients (14) .
The formation of ,BGPI/phospholipids complex is to facilitate the clearance of apoptotic cells (28) . In theory, the production of apGPI would be expected to increase in parallel to an advance of hypertension and development of cardiovascular complications, such as cerebral ischemia or coronary artery disease. A normal blood apGPI level in my hypertensive patients and Sherer and colleagues' (17) patients may have two possibilities: an absence of humoral response to produce apGPI or a pseudo-normal blood ajGPI in them.
The latter is believed as an increase of blood a,BGPI level has been identified in cerebral ischemia (15) , angina (29) , or myocardial infarct patients (30) . The mechanisms of pseudo-normal blood a,GPI may be a) an activation of T suppressor cell, antigen blocking effect, receptor cross-link or anti-antibody production; b) urinary overexcretion of afGPI (16); c) a low total immunoglobulins; or d) overconsumption of af3GPI, such as binding with atherosclerotic plaque (31) or immune complex formation. Given that I do not examine all tests listed, the precise mechanism is far from conclusion herein. Nevertheless, a normal blood a3GPI level does not come from a low total protein or immunoglobulin level in my patients because the serum total protein and globulin levels are no different between hypertensive or normotensive subjects. Additionally, afGPI increases in diabetes mellitus, dyslipidemia, and in men. It is reasonable to believe that a higher circulatory PGPI provides an excessive 3GPI/phospholipids complex for afGPI production in patients such as in the series of Frostegard and associates (14) .
In conclusion, an increase in blood apGPI level is identified in hypertensive and normotensive patients with cerebral ischemia. This finding sug-gests a vital role of afGPI for cerebral ischemia in both conditions. An understanding of humoral autoimmunity in cerebral ischemia warrants further investigation.
